miR‑96 promotes invasion and metastasis by targeting GPC3 in non‑small cell lung cancer cells

Fei,Xiubin; Zhang,Jingang; Zhao,Yunwei; Sun,Meijia; Zhao,Haifeng; Li,Shuang

doi:10.3892/ol.2018.8507

miR‑96 promotes invasion and metastasis by targeting GPC3 in non‑small cell lung cancer cells

Authors:
- Xiubin Fei
- Jingang Zhang
- Yunwei Zhao
- Meijia Sun
- Haifeng Zhao
- Shuang Li
View Affiliations

Affiliations: Department of Geriatrics, First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154003, P.R. China, Department of Bone Surgery, Jiamusi Central Hospital, Jiamusi, Heilongjiang 154003, P.R. China, Department of Respiratory Medicine, First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154003, P.R. China
Published online on: April 16, 2018 https://doi.org/10.3892/ol.2018.8507
Pages: 9081-9086

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is a major cause of death worldwide, and non‑small cell lung cancer (NSCLC) is the most common type of lung cancer. The aim of this study was to investigate whether miR‑96 mediated the invasion and metastasis of NSCLC by targeting glypican‑3 (GPC3). Reverse transcription‑quantitative PCR (RT‑qPCR) was employed to detect the level of miR‑96 and GPC3 mRNA. We applied western blot analysis to measure the protein expression level of GPC3 gene. The luciferase reporter assay was employed to confirm that GPC3 was a target gene of miR‑96. The Transwell assay was used to detect migration and invasion. The results revealed that miR‑96 was upregulated in NSCLC tissues and lung cancer cells (A549 and H460) compared with corresponding paracancerous tissues and normal epidermic MRC‑5 cells. Overexpression of miR‑96 promoted invasion and migration in A549 cells. GPC3 was a direct target of miR‑96 and regulated by miR‑96. GPC3 could reverse partial fuction of miR‑96 on proliferation. In conclusion, miR‑96 was able to promote the migration and invasion of lung cancer cells by targeting GPC3 gene. The newly identified miR‑96/GPC3 axis may provide a therapeutic method for the treatment of NSCLC.

View Figures

View References

1	Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Islami F, Torre LA and Jemal A: Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 4:327–338. 2015.PubMed/NCBI
4	Subramanian J and Govindan R: Lung cancer in never smokers: A review. J Clin Oncol. 25:561–570. 2007. View Article : Google Scholar : PubMed/NCBI
5	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
6	Zhang Y, Wang DC, Shi L, Zhu B, Min Z and Jin J: Genome analyses identify the genetic modification of lung cancer subtypes. Semin Cancer Biol. 42:20–30. 2017. View Article : Google Scholar : PubMed/NCBI
7	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
8	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
9	Sittka A and Schmeck B: MicroRNAs in the lung. Adv Exp Med Biol. 774:121–134. 2013. View Article : Google Scholar : PubMed/NCBI
10	Ke Y, Zhao W, Xiong J and Cao R: Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells. FEBS Lett. 587:3153–3157. 2013. View Article : Google Scholar : PubMed/NCBI
11	Han H, Yang J, Wang Y, Chen W, Chen J, Yang Y and Li Q: Nucleobase-modified polyamidoamine-mediated miR-23b delivery to inhibit the proliferation and migration of lung cancer. Biomater Sci. 5:2268–2275. 2017. View Article : Google Scholar : PubMed/NCBI
12	Ma Q, Jiang Q, Pu Q, Zhang X, Yang W, Wang Y, Ye S, Wu S, Zhong G, Ren J, et al: MicroRNA-143 inhibits migration and invasion of human non-small-cell lung cancer and its relative mechanism. Int J Biol Sci. 9:680–692. 2013. View Article : Google Scholar : PubMed/NCBI
13	Xu S, Witmer PD, Lumayag S, Kovacs B and Valle D: MicroRNA (miRNA) transcriptome of mouse retina and identification of a sensory organ-specific miRNA cluster. J Biol Chem. 282:25053–25066. 2007. View Article : Google Scholar : PubMed/NCBI
14	Hong Y, Liang H, Uzair-Ur-Rehman, Wang Y, Zhang W, Zhou Y, Chen S, Yu M, Cui S, Liu M, et al: miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer. Sci Rep. 6:374212016. View Article : Google Scholar : PubMed/NCBI
15	Ress AL, Stiegelbauer V, Winter E, Schwarzenbacher D, Kiesslich T, Lax S, Jahn S, Deutsch A, Bauernhofer T, Ling H, et al: MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients. Mol Carcinog. 54:1442–1450. 2015. View Article : Google Scholar : PubMed/NCBI
16	Wu L, Pu X, Wang Q, Cao J, Xu F, Xu LI and Li K: miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9. Oncol Lett. 11:945–952. 2016. View Article : Google Scholar : PubMed/NCBI
17	Guo H, Li Q, Li W, Zheng T, Zhao S and Liu Z: MiR-96 downregulates RECK to promote growth and motility of non-small cell lung cancer cells. Mol Cell Biochem. 390:155–160. 2014. View Article : Google Scholar : PubMed/NCBI
18	Jalvy-Delvaille S, Maurel M, Majo V, Pierre N, Chabas S, Combe C, Rosenbaum J, Sagliocco F and Grosset CF: Molecular basis of differential target regulation by miR-96 and miR-182: The Glypican-3 as a model. Nucleic Acids Res. 40:1356–1365. 2012. View Article : Google Scholar : PubMed/NCBI
19	Cai Z, Grobe K and Zhang X: Role of heparan sulfate proteoglycans in optic disc and stalk morphogenesis. Dev Dyn. 243:1310–1316. 2014. View Article : Google Scholar : PubMed/NCBI
20	Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J and Zako M: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 68:729–777. 1999. View Article : Google Scholar : PubMed/NCBI
21	Murthy SS, Shen T, De Rienzo A, Lee WC, Ferriola PC, Jhanwar SC, Mossman BT, Filmus J and Testa JR: Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene. 19:410–416. 2000. View Article : Google Scholar : PubMed/NCBI
22	White GR, Kelsey AM, Varley JM and Birch JM: Somatic glypican 3 (GPC3) mutations in Wilms' tumour. Br J Cancer. 86:1920–1922. 2002. View Article : Google Scholar : PubMed/NCBI
23	Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
24	Filmus J: Glypicans in growth control and cancer. Glycobiology. 11:19R–23R. 2001. View Article : Google Scholar : PubMed/NCBI
25	Ho M and Kim H: Glypican-3: A new target for cancer immunotherapy. Eur J Cancer. 47:333–338. 2011. View Article : Google Scholar : PubMed/NCBI
26	Li L, Jin R, Zhang X, Lv F, Liu L, Liu D, Liu K, Li N and Chen D: Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma. Hepatology. 56:1380–1390. 2012. View Article : Google Scholar : PubMed/NCBI